Common Stock Purchase and Registration Rights Agreement between NovaBay Pharmaceuticals, Inc. and Institutional Investor (March 25, 2019)

Summary

NovaBay Pharmaceuticals, Inc. has agreed to sell up to $3,000,000 of unregistered common stock to an institutional investor. The purchase price is set at 90% of the lowest traded price within five days before the closing date, which occurs five days after NovaBay notifies the investor. NovaBay will file a registration statement by April 1, 2019, to allow resale of the shares. The investor cannot own more than 9.9% of NovaBay’s stock. NovaBay will also donate 150,000 shares to the investor’s manager to support a student-run fund and pay a $15,000 document preparation fee.

EX-10.1 2 ex_139225.htm EXHIBIT 10.1 ex_139225.htm

Exhibit 10.1

 

 

        March 25, 2019

 

Issuer

NovaBay Pharmaceuticals, Inc., a Delaware company

   

Investor

Institutional Investor

   

Securities

Unregistered Common Stock, with registration rights; Closing Date conditional on effectiveness of resale registration statement

   

Investment

Up to $3,000,000

   

Purchase Price

Lowest traded price of Securities within five days prior to Closing Date multiplied by 90%

   

Purchase Notice

Date Issuer notifies Investor of election to sell Securities

   

Closing Date

Five days after Purchase Notice

   

Ownership Limitation

9.9%

   

Securities Exemption

Regulation D; Form D will be filed with the SEC

   

Registration

Issuer will file Registration Statement to Register the Securities and Donation on Form S-3 by April 1, 2019

   

Documentation

Common Stock Purchase Agreement, Registration Rights Agreement and Donation Letter Agreement

   

Document Preparation Fee

Issuer will pay Investor $15,000 upon execution of closing documents

   

Donation

 

Issuer will donate 150,000 Securities to Institutional Investor, manager of Investor, upon executing closing documents to support cost of student-run fund

Agreed and Accepted:

 

 

By:

  /s/ Justin Hall   

 

 

 

Justin Hall, Esq. 

 

 

 

NovaBay Pharmaceuticals, Inc.

CEO and General Counsel

 

 

 

 

 

 

By:

  /s/  [Redacted]

 

 

 

[Redacted] 

 

 

 

Title: Authorized Signatory  

 

 

 

1